In this issue of Blood, a novel approach to the treatment of T-acute lymphoblastic leukemia (T-ALL) using chimeric antigen receptor (CAR) T cells redirected against CD1a1 in in vitro and xenograft models.CD1a is a transmembrane glycoprotein that presents self or bacterial derived lipids to specialized T cells.Importantly, when anti-CD1a CAR T cells were incubated with fetal thymocytes, the majority of cells were preserved, indicating this therapy might not induce thymic ablation.CAR T-cell therapy for T-ALL and offers hope that the considerable success of CAR T cells in B-ALL can soon be extended to patients with T-ALL.